#China #Suzhou #RNA Therapeutics #Ribo Life Science #siRNA Technology

Ribo Life Science to Showcase Ex-Hepatic Delivery Data

Suzhou Ribo Life Science Co., Ltd., often referred to as Ribo, is making headlines for its upcoming presentation at the RNA Leaders Europe Conference in Vienna, Austria, on March 19th. This conference is widely regarded as one of the premier gatherings for experts in the field of oligonucleotides. Ribo, with the Hong Kong Stock Exchange code 6938, has been invited to highlight its advances in ex-hepatic delivery systems, marking a major milestone for the company.

Ribo's commitment to innovation is underscored by its successful RiboGalSTAR™ technology, which specifically targets liver-related genes across several clinical programs. With seven clinical programs in progress and notable worldwide collaborations and licensing deals valued in excess of $6 billion, Ribo is at the forefront of siRNA technology.

The focus of Ribo's presentation will shift to its proprietary delivery platform, RiboPepSTAR™, which has enabled the targeted delivery of small interfering RNA (siRNA) beyond the liver to critical organs. The platform has particularly excelled in achieving effective delivery to the kidneys, with preclinical data illustrating specific uptake in proximal tubular regions and successful mRNA knockdown across different species, including rodents and non-human primates. This data indicates promising results for applications in miscellaneous disease models.

Beyond the kidneys, Ribo is actively pursuing preclinical development for targeted drug candidates aimed at treating conditions within the cardiovascular system, adipose tissue, muscular disorders, and central nervous system ailments. By leveraging the capabilities of the RiboPepSTAR™ platform, the company is poised to significantly broaden its therapeutic offerings, venturing into ex-hepatic treatment modalities that may revolutionize patient care on a global scale.

Ribo's continued advancement in creating siRNA therapeutics is expected to facilitate innovative treatment options for patients worldwide. As biotechnology and pharmaceutical landscapes evolve, Ribo remains steadfast in its mission to enhance the efficacy and reach of RNA-based therapeutics. Such developments will likely spur continued interest in RNA technologies, heralding a future of unparalleled treatment possibilities in the field of medicine.

Moreover, as Ribo solidifies its standing in the industry through both innovation and collaboration, the implications of these advancements may resonate well beyond the conference, influencing future research and development strategies across the life sciences sector. Ribo's participation in this prestigious event is not only a testament to its achievements but also an invitation for further dialogue and partnership within the scientific community.

In conclusion, Ribo's upcoming presentation at the RNA Leaders Europe Conference represents a significant opportunity to showcase its breakthroughs in ex-hepatic delivery technology, further positioning the company as a leader in the field. Researchers, clinicians, and industry stakeholders alike will be keenly observing Ribo's progress as it seeks to transform therapeutic landscapes through cutting-edge RNA solutions.